These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Change in novel filtration markers and risk of ESRD.
    Author: Rebholz CM, Grams ME, Matsushita K, Selvin E, Coresh J.
    Journal: Am J Kidney Dis; 2015 Jul; 66(1):47-54. PubMed ID: 25542414.
    Abstract:
    BACKGROUND: Chronic kidney disease progression is a risk factor for end-stage renal disease (ESRD). A 57% decline in creatinine-based estimated glomerular filtration rate (eGFRcr) is an established surrogate outcome for ESRD in clinical trials, and a 30% decrease recently has been proposed as a surrogate end point. However, it is unclear whether change in novel filtration marker levels provides additional information for ESRD risk to change in eGFRcr. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: Atherosclerosis Risk in Communities (ARIC) Study participants from 4 US communities. PREDICTORS: Percent change in levels of filtration markers (eGFRcr, cystatin C-based eGFR [eGFRcys], the inverse of β2-microglobulin concentration [1/B2M]) over a 6-year period. OUTCOME: Incident ESRD. MEASUREMENTS: Cox proportional hazards regression with adjustment for demographics, kidney disease risk factors, and first measurement of eGFRcr. RESULTS: During a median follow-up of 13 years, there were 142 incident ESRD cases. In adjusted analysis, declines > 30% in eGFRcr, eGFRcys, and 1/B2M were associated significantly with ESRD compared with stable concentrations of filtration markers (HRs of 19.96 [95% CI, 11.73-33.96], 16.67 [95% CI, 10.27-27.06], and 22.53 [95% CI, 13.20-38.43], respectively). Using the average of declines in the 3 markers, >30% decline conferred higher ESRD risk than that for eGFRcr alone (HR, 31.97 [95% CI, 19.40-52.70; P=0.03] vs eGFRcr). LIMITATIONS: Measurement error could influence estimation of change in filtration marker levels. CONCLUSIONS: A >30% decline in kidney function assessed using novel filtration markers is associated strongly with ESRD, suggesting the potential utility of measuring change in cystatin C and B2M levels in settings in which improved outcome ascertainment is needed, such as clinical trials.
    [Abstract] [Full Text] [Related] [New Search]